FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2799487694> ?p ?o ?g. }

• W2799487694 endingPage "2306" @default.
• W2799487694 startingPage "2297" @default.
• W2799487694 abstract "The treatment of metastatic castration-resistant prostate cancer (mCRPC) remains challenging with current treatment options. The development of more effective therapies is, therefore, urgently needed. Targeted radionuclide therapy with prostate-specific membrane antigen (PSMA)-targeting ligands has revealed promising clinical results. In an effort to optimize this concept, it was the aim of this study to design and investigate PSMA ligands comprising different types of albumin binders. PSMA-ALB-53 and PSMA-ALB-56 were designed by combining the glutamate-urea-based PSMA-binding entity, a DOTA chelator and an albumin binder based on the 4-( p-iodophenyl)-moiety or p-(tolyl)-moiety. The compounds were labeled with 177Lu (50 MBq/nmol) resulting in radioligands of high radiochemical purity (≥98%). Both radioligands were stable (≥98%) over 24 h in the presence of l-ascorbic acid. The uptake into PSMA-positive PC-3 PIP tumor cells in vitro was in the same range (54-58%) for both radioligands; however, 177Lu-PSMA-ALB-53 showed a 15-fold enhanced binding to human plasma proteins. Biodistribution studies performed in PC-3 PIP/flu tumor-bearing mice revealed high tumor uptake of 177Lu-PSMA-ALB-53 and 177Lu-PSMA-ALB-56, respectively, demonstrated by equal areas under the curves (AUCs) for both radioligands. The increased retention of 177Lu-PSMA-ALB-53 in the blood resulted in almost 5-fold lower tumor-to-blood AUC ratios when compared to 177Lu-PSMA-ALB-56. Kidney clearance of 177Lu-PSMA-ALB-56 was faster, and hence, the tumor-to-kidney AUC ratio was 3-fold higher than in the case of 177Lu-PSMA-ALB-53. Due to the more favorable tissue distribution profile, 177Lu-PSMA-ALB-56 was selected for a preclinical therapy study in PC-3 PIP tumor-bearing mice. The tumor growth delay after application of 177Lu-PSMA-ALB-56 and 177Lu-PSMA-617 applied at the same activities (2 or 5 MBq per mouse) revealed better antitumor effects in the case of 177Lu-PSMA-ALB-56. As a consequence, the survival of mice treated with 177Lu-PSMA-ALB-56 was prolonged when compared to the mice, which received the same activity of 177Lu-PSMA-617. Our results demonstrated the superiority of 177Lu-PSMA-ALB-56 over 177Lu-PSMA-ALB-53 indicating that the p-(tolyl)-moiety was more suited as an albumin binder to optimize the tissue distribution profile. 177Lu-PSMA-ALB-56 was more effective to treat tumors than 177Lu-PSMA-617 resulting in complete tumor remission in four out of six mice. This promising results warrant further investigations to assess the potential for clinical application of 177Lu-PSMA-ALB-56." @default.
• W2799487694 created "2018-05-17" @default.
• W2799487694 creator A5024922998 @default.
• W2799487694 creator A5027923729 @default.
• W2799487694 creator A5041743198 @default.
• W2799487694 creator A5056614563 @default.
• W2799487694 date "2018-04-23" @default.
• W2799487694 modified "2023-10-12" @default.
• W2799487694 title "Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy" @default.
• W2799487694 cites W2014999922 @default.
• W2799487694 cites W2030940240 @default.
• W2799487694 cites W2072982730 @default.
• W2799487694 cites W2112451160 @default.
• W2799487694 cites W2112979860 @default.
• W2799487694 cites W2123985787 @default.
• W2799487694 cites W2137571973 @default.
• W2799487694 cites W2147136637 @default.
• W2799487694 cites W2164365729 @default.
• W2799487694 cites W2229603522 @default.
• W2799487694 cites W2397136240 @default.
• W2799487694 cites W2513308461 @default.
• W2799487694 cites W2525124727 @default.
• W2799487694 cites W2525349940 @default.
• W2799487694 cites W2532226140 @default.
• W2799487694 cites W2577557925 @default.
• W2799487694 cites W2578311142 @default.
• W2799487694 cites W2610081635 @default.
• W2799487694 cites W2611673620 @default.
• W2799487694 cites W2612014481 @default.
• W2799487694 cites W2620891707 @default.
• W2799487694 cites W2731354724 @default.
• W2799487694 cites W2752389930 @default.
• W2799487694 cites W2766371188 @default.
• W2799487694 cites W2786988345 @default.
• W2799487694 doi "https://doi.org/10.1021/acs.molpharmaceut.8b00152" @default.
• W2799487694 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29684274" @default.
• W2799487694 hasPublicationYear "2018" @default.
• W2799487694 type Work @default.
• W2799487694 sameAs 2799487694 @default.
• W2799487694 citedByCount "93" @default.
• W2799487694 countsByYear W27994876942018 @default.
• W2799487694 countsByYear W27994876942019 @default.
• W2799487694 countsByYear W27994876942020 @default.
• W2799487694 countsByYear W27994876942021 @default.
• W2799487694 countsByYear W27994876942022 @default.
• W2799487694 countsByYear W27994876942023 @default.
• W2799487694 crossrefType "journal-article" @default.
• W2799487694 hasAuthorship W2799487694A5024922998 @default.
• W2799487694 hasAuthorship W2799487694A5027923729 @default.
• W2799487694 hasAuthorship W2799487694A5041743198 @default.
• W2799487694 hasAuthorship W2799487694A5056614563 @default.
• W2799487694 hasConcept C112705442 @default.
• W2799487694 hasConcept C121608353 @default.
• W2799487694 hasConcept C126322002 @default.
• W2799487694 hasConcept C178790620 @default.
• W2799487694 hasConcept C185592680 @default.
• W2799487694 hasConcept C197404232 @default.
• W2799487694 hasConcept C202751555 @default.
• W2799487694 hasConcept C2776125364 @default.
• W2799487694 hasConcept C2777807558 @default.
• W2799487694 hasConcept C2779931791 @default.
• W2799487694 hasConcept C2780192828 @default.
• W2799487694 hasConcept C2993559085 @default.
• W2799487694 hasConcept C502942594 @default.
• W2799487694 hasConcept C55493867 @default.
• W2799487694 hasConcept C71924100 @default.
• W2799487694 hasConcept C98274493 @default.
• W2799487694 hasConceptScore W2799487694C112705442 @default.
• W2799487694 hasConceptScore W2799487694C121608353 @default.
• W2799487694 hasConceptScore W2799487694C126322002 @default.
• W2799487694 hasConceptScore W2799487694C178790620 @default.
• W2799487694 hasConceptScore W2799487694C185592680 @default.
• W2799487694 hasConceptScore W2799487694C197404232 @default.
• W2799487694 hasConceptScore W2799487694C202751555 @default.
• W2799487694 hasConceptScore W2799487694C2776125364 @default.
• W2799487694 hasConceptScore W2799487694C2777807558 @default.
• W2799487694 hasConceptScore W2799487694C2779931791 @default.
• W2799487694 hasConceptScore W2799487694C2780192828 @default.
• W2799487694 hasConceptScore W2799487694C2993559085 @default.
• W2799487694 hasConceptScore W2799487694C502942594 @default.
• W2799487694 hasConceptScore W2799487694C55493867 @default.
• W2799487694 hasConceptScore W2799487694C71924100 @default.
• W2799487694 hasConceptScore W2799487694C98274493 @default.
• W2799487694 hasIssue "6" @default.
• W2799487694 hasLocation W27994876941 @default.
• W2799487694 hasLocation W27994876942 @default.
• W2799487694 hasOpenAccess W2799487694 @default.
• W2799487694 hasPrimaryLocation W27994876941 @default.
• W2799487694 hasRelatedWork W2005829956 @default.
• W2799487694 hasRelatedWork W2053638145 @default.
• W2799487694 hasRelatedWork W2066403337 @default.
• W2799487694 hasRelatedWork W2165824272 @default.
• W2799487694 hasRelatedWork W2171197182 @default.
• W2799487694 hasRelatedWork W2279994500 @default.
• W2799487694 hasRelatedWork W2586846067 @default.
• W2799487694 hasRelatedWork W2591911969 @default.
• W2799487694 hasRelatedWork W3119204130 @default.
• W2799487694 hasRelatedWork W4304183732 @default.

• next